The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of breast cancer in Black patients.

The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of breast and prostate cancer in Black patients.

With expanding treatment options, clinicians are challenged to understand important criteria used in selecting optimal first- and subsequent-line therapies for individuals with metastatic breast cancer. Staying up-to-date with the available treatment options is important to integrate new evidence-based data into their clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.
Few survivors meet all health behavior recommendations, and clinicians often report a lack of expertise, time, and resources to address healthy lifestyles with cancer survivors. Education on this topic can help clinicians encourage and support survivors to maintain and enhance their wellness.
Clinicians need to know what, when, and how to test and how to make subsequent informed, patient‐personalized treatment decisions. Accurate interpretation of results is critical; over-interpretation or misinterpretation will lead to treatment of patients with ineffective and expensive therapies, negatively impacting patient outcomes.
In order to define clinical situations that require appropriate locoregional therapies and use the right approach, clinicians need to stay up-to-date on the updates as well as the controversies.
By staying up-to-date on new approaches and options for neoadjuvant /adjuvant systemic therapy, the clinicians will be able to provide appropriate care using a shared decision-making process with the patient, taking into account patient and disease characteristics including risk of recurrence, and weighing the potential benefits and risks of each option. In addition, it is important for clinicians to be aware of new supportive care interventions available to improve the quality of life of patients.
Clinicians need to recognize that these disparities exist and the causes for the disparities to optimally manage their patients with breast cancer.

This program will provide expert insights on the current recommendations of care for patients with breast cancer and include the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.

Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practice remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which agents already exist or are currently being developed. Within recent years, PD-L1 inhibition is being studied in trials as a new avenue for treatment options in these patients. Current evidence demonstrates increased benefit when using these agents in combination with chemotherapy.

Pages

Subscribe to RSS - Breast Cancer